Camurus AB (publ) commercializes and develops medicines for severe and chronic conditions.
Business Segments
The company operates five segments includes Clinical Development, Commercialization, Regulatory Affairs, Global Partnerships, and Technolog…
Analysis
Beloved champion
Camurus AB (publ) sits in the top corner of our grid: excellent business, premium price; every investor already knows the story.
On valuation, the picture is expensive. The owner-earnings multiple stands at 57.4×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 20% a year, against analyst forecasts of 60%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is sturdy. The company scores 14/20 on our value-creation score: strong value creator.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202356
49
2023202420252026
All-time high
88
Mar 2026
All-time low
49
Jun 2026
Average rank
67
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
19
3
5
31
Price/Earnings
11
14
6
25
Price/Book
30
3
5
12
Dividend Yield
1
1
1
1
Value (overall)
1
4
1
8
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.